Ultragenyx Pharmaceutical Inc stock is traded at $16.70, with a volume of 5,592,538. It is up +5.03% in the last 24 hours and up +14.86% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Previous Close:
$15.90
Open:
$15.94
24h Volume:
5,592,538
Relative Volume:
1.27
Market Cap:
$1.70B
Revenue:
$669.43M
Net Income/Loss:
-$609.36M
P/E Ratio:
-
EPS:
-$6.11
Net Cash Flow:
-$507.20M
1W Performance:
0.00%
1M Performance:
+14.86%
6M Performance:
-30.96%
1Y Performance:
-49.13%
1-Day Range:
$15.65$16.74
1-Week Range:
$15.65$16.74
52-Week Range:
$12.73$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical IncSector
HealthcareIndustry
BiotechnologyPhone
415-483-8800Address
60 LEVERONI COURT, NOVATO, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS